ArticleJournal of translational medicine2026

Engineered PD1-NKG2D Dual-CAR NK92 cells broaden antitumor target recognition in preclinical tumor models.

Xinru Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.